On May 29, 2018 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies reported it will participate in two upcoming investor conferences (Press release, Halozyme, MAY 29, 2018, View Source [SID1234527084]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Helen Torley, president and chief executive officer will represent Halozyme in a question and answer session at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes on Tuesday, June 12 at 6:20 p.m. ET / 3:20 p.m. PT.

On Wednesday, June 20, Laurie Stelzer, senior vice president and chief financial officer will represent Halozyme in a question and answer session at the 2018 JMP Securities Life Sciences Conference in New York at 2:30 p.m. ET / 11:30 a.m. PT.

Webcasts of both sessions can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

On May 29, 2018 Nordic Nanovector ASA (OSE: NANO) reported that its pivotal PARADIGME Phase 2b trial with Betalutin (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional Committees for Medical and Health Research Ethics (REK) in Norway (Press release, Nordic Nanovector, MAY 29, 2018, View Source [SID1234553503]). Nordic Nanovector has now received all necessary approvals to begin PARADIGME in Norway and will commence start-up activities with the selected clinical sites immediately with the intention of recruiting patients into the study as soon as possible.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PARADIGME is a global, randomised Phase 2b clinical trial comparing two promising Betalutin dosing regimens in patients with third-line follicular lymphoma who are refractory to anti-CD20 immunotherapy (including rituximab), a population with a high unmet medical need. The trial will enrol 130 patients at 80-85 sites in approximately 20 countries. The first patient is expected to be dosed in the first half of 2018 and the data read-out is targeted to the first half of 2020.

On May 29, 2018 Splash Pharmaceuticals, Inc. ("Splash"), a closely held private biopharmaceutical company that develops novel cancer therapies, reported the presentation of an abstract related to the clinical trial of SPL-108 in platinum-resistant ovarian cancer patients (Press release, Splash Pharmaceuticals, MAY 29, 2018, View Source [SID1234526926]). The Phase I trial is being conducted at Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, and the abstract will be presented by its first author Dr. Eugenia Girda, a member of the Institute’s Gynecologic Oncology Program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2018 Annual meeting in Chicago, IL.

Poster Discussion: Monday June 4, 2018 from 1:15 p.m. – 4:45 p.m. (CDT)

An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer.

Poster Presentation: Abstract #TPS5608, Poster Board #331a, Hall A

View Source

On May 29, 2018 BerGenBio ASA (OSE: BGBIO) reported it will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib (Press release, BerGenBio, MAY 29, 2018, View Source [SID1234527034]). The data will be presented at the Annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting and at a reception hosted by BerGenBio (details below).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call details:
The call will be hosted by BerGenBio senior management and take place on:
Monday, 4 June 2018 at 8:30 AM CEST.
To take part, please dial in 5-10 minutes prior to the scheduled start using below phone number and confirmation code 1068189:

Norway +47 2100 2608
United Kingdom +44 (0)330 336 9106
United States +1 323-794-2594

A slide deck presentation to accompany the call will be made available at www.bergenbio.com in the Investors / Presentations section from 8:00 AM CEST on 4 June 2018.

Presentations to be made during the annual ASCO (Free ASCO Whitepaper) meeting:
Saturday 2 June, 6:00 – 8:00 PM CDT, Chicago School of the Art Institute, Chicago, IL
BerGenBio private reception

New interim Phase II clinical trial data with bemcentinib and selected pre-clinical data to be discussed by BerGenBio principal investigators and invited key opinion leaders
For further details and to receive an invitation, please click here
Monday 4 June, 8:00 AM – 11:30 AM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBC008 – Poster Board: #292, Abstract 3078
Interim clinical data from clinical trial ref. BGBC003 – Poster Board: #80, Abstract 7020
To be discussed at the Poster Discussion Session. 11:30 AM – 12:45 PM
Biomarker study – Poster Board: #385, Abstract 2559
Monday 4 June, 1:15 PM – 4:45 PM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBIL006 – Poster Board: #375, Abstract 9548
The posters presented at ASCO (Free ASCO Whitepaper) will be made available www.bergenbio.com in the Investors / Presentations section at the time of presentation.

On May 29, 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 (Press release, AbbVie, MAY 29, 2018, View Source [SID1234527051]). Richard A. Gonzalez, chairman and chief executive officer, will present at 10 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.